Urocit®-K 15 mEq (1620 mg) potassium citrate

Switch to mobile view »

The next generation in stone control therapy

Kidney stones affect more than a million Americans each year. Twelve to 24 million Americans will develop stones in their lifetime and the incidence rate has increased dramatically over the last 20 years with approximately 1,000,000 new stone cases reported each year.

If you've had a kidney stone, you know how much it hurts. But even though it's hard to forget the pain, over time it can be easy to forget the diet guidelines and daily medications that help prevent new stones. The truth is, patients who form just one kidney stone have a 50% higher risk of forming another stone in the next 5 to 10 years. If you've already had two or more stones, your risks of forming additional stones can be even higher.1

That's why continued compliance is your best protection against another kidney stone attack. But for many patients, it can be a real challenge to keep up with multitablet, multidose medication therapies.2,3

Simplify the dose.

Introducing new Urocit®-K 15 mEq—a maximum-strength alkalinizing agent for simple BID dosing in the treatment of recurrent nephrolithiasis.

Powerful dosage strength

New Urocit-K 15 mEq contains 50% more active ingredient than Urocit-K 10 mEq

Streamlined control

Maintain targeted urinary citrate and urinary pH levels with fewer daily tablets

Proven efficacy

Potassium citrate has been proven to inhibit formation of calcium oxalate and uric acid stones,4,5,6 with a clinical success rate of more than 90%7,8,9

Strengthen the compliance

Medication management is a proven tool for inhibiting stone formation. Yet patient adherence to multitablet, multidose therapy regimens remains a significant challenge.10,11

  • Welcome simplicity — more concentrated formula simplifies complex dosing schedules
  • Enhanced compliance — in clinical studies, less frequent dosing regimens demonstrate better compliance12
  • Comfortable formula — slow-release wax-matrix delivery system for extended release in the GI tract enhances tolerability and provides uniform increases in urinary citrate levels7,13

Urocit-K is indicated for the treatment of calcium and uric acid kidney stones. Urocit-K is also available in slow-release wax-matrix tablets in 540 mg and 1080 mg strengths.

Related Information
Package Insert»
Urocit-K Website»
StoneDisease.org»

Important Safety Information

Contraindications

  • Patients with hyperkalemia, peptic ulcer disease, active urinary tract infection, and renal insufficiency
  • Conditions predisposing patients to hyperkalemia, including chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, and extensive tissue breakdown

Warnings and Precautions

  • Hyperkalemia: In patients with impaired mechanisms for excreting potassium, Urocit-K administration can produce hyperkalemia and cardiac arrest. Potentially fatal hyperkalemia can develop rapidly and be asymptomatic. The use of Urocit-K in patients with chronic renal failure, or any other condition which impairs potassium excretion such as severe myocardial damage or heart failure, should be avoided
  • Gastrointestinal lesions: If there is severe vomiting, abdominal pain or gastrointestinal bleeding, Urocit-K should be discontinued immediately and the possibility of bowel perforation or obstruction investigated

Patient Counseling Information

Administration of Drug
  • Patients should be told to take Urocit-K 15 mEq without crushing, chewing, or sucking the tablet
  • Patients should be told to take Urocit-K 15 mEq only as directed, especially if the patient is also taking both diuretics and digitalis preparations
  • Patients should be told to check with the doctor if they experience difficulty swallowing the tablet or it seems to stick in the throat
  • Patients should be told to check with the doctor at once if they notice tarry stools or other signs of gastrointestinal bleeding
  • Patients should be advised that regular blood tests and electrocardiograms will be performed to ensure safety

Patient Monitoring Information

Hyperkalemia

  • Patients with impaired mechanisms for excreting potassium should be closely monitored for signs of hyperkalemia with periodic blood tests and ECGs

This material is intended to provide basic information. Patients should discuss all medical advice, diagnosis, and treatment with their healthcare provider.

Please see full Prescribing Information

  1. Chandhoke PS.. Evaluation of the recurrent stone former. Urol Clin North Am. 2007 Aug;34(3):315-22.
  2. Lotan Y. Economics and cost of care of kidney stone disease. Advances Chronic Kidney Dis. 2009;16:5-10.
  3. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296-1310.
  4. Pak CY, Fuller C, Sakhaee K, Preminger GM, Britton F. Long-term treatment of calcium nephrolithiasis with potassium citrate. J Urol. 1985 Jul;134(1):11-9.
  5. Preminger GM, Sakhaee K, Skurla C, Pak CY. Prevention of recurrent calcium stone formation with potassium citrate therapy in patients with distal renal tubular acidosis. J Urol. 1985 Jul;134(1):20-3.
  6. Pak CY, Peterson R, Sakhaee K, Fuller C, Preminger G, Reisch J. Correction of hypocitraturia and prevention of stone formation by combined thiazide and potassium citrate therapy in thiazide-unresponsive hypercalciuric nephrolithiasis. Am J Med. 1985 Sep;79(3):284-8.
  7. Pak CYC. Hypocitraturic calcium nephrolithiasis. In: Resnick MI, Pak CYC, eds. Urolithiasis: A Medical and Surgical Reference. Philadelphia, PA: WB Saunders Company; 1990:89-103.
  8. Riese RJ, Sakhaee K. Uric acid nephrolithiasis: pathogenesis and treatment. J Urol. 1992 Sep;148(3):765-71.
  9. Barcelo P, Wuhl O, Servitge E, Rousaud A, Pak CY. Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol. 1993 Dec;150(6):1761-4.
  10. Chandhoke PS. Evaluation of the recurrent stone former. Urol Clin North Am. 2007 Aug;34(3):315-22.
  11. Lotan Y. Economics and cost of care of kidney stone disease. Advances Chronic Kidney Dis. 2009;16:5-10.
  12. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296-1310.
  13. Pak CY, Skurla C, Brinkley L, Sakhaee K. Augmentation of renal citrate excretion by oral potassium citrate administration: time course, dose frequency schedule, and dose-response relationship. J Clin Pharmacol. 1984 Jan;24(1):19-26.
More than 500,000 babies are born too soon each year. Some are so small they struggle to survive. This year, Mission Pharmacal is joining forces with the March of Dimes* as a National Corporate Sponsor to help raise awareness about the growing crisis of premature birth. To learn more and help us fight prematurity, click on the links below. For more than 60 years, Mission Pharmacal has been committed to providing products for healthy women and healthy babies.
Learn moreDonate
Share on FacebookShare on MySpaceShare on TwitterShare on DiggShare on Yahoo! Buzz
Share on StumbleUponShare on redditShare on TechnoratiShare on del.icio.usShare on LinkedIn